GLP-1
-
healthFDA Cites Novo Nordisk for Failing to Report Patient Deaths Linked to GLP-1 Drugs
The FDA issued a warning letter accusing Novo Nordisk of systemic failures in reporting serious side effects-including deaths-of patients using Ozempic and Wegovy.
-
healthWeight Loss Drug Users Conceal Treatment Amid Social Stigma
A new survey reveals two-thirds of weight loss drug users hide their treatment, facing judgment and misconceptions about medical weight management.
-
healthGLP-1 Drugs Show Promise as Addiction 'Habit-Breakers'
New research suggests GLP-1 medications like Ozempic and Wegovy may significantly reduce addiction risks and substance-related deaths across various substances.
-
healthOzempic-Like Drugs Linked to Increased Bone and Joint Condition Risk
New study suggests GLP-1 medications like Ozempic may slightly elevate risks of osteoporosis, gout, and osteomalacia, prompting calls for bone health monitoring.
-
healthGLP-1 Drugs Linked to Increased Fracture, Osteoporosis, and Gout Risk in New Studies
New research suggests GLP-1 medications like Ozempic and Wegovy may elevate fracture risk and exacerbate osteoporosis and gout, particularly in older adults.
-
healthFDA Cracks Down on 30 Telehealth Firms Over Illegal GLP-1 Marketing
The FDA has issued warning letters to 30 telehealth companies for misleading marketing of GLP-1 products, including false claims and obscured sourcing.
-
healthWeight-Loss Drugs Show Promise in Preventing Heart Attack Complications
New research suggests GLP-1 drugs, known for weight loss, could significantly reduce cardiac risks by opening blocked blood vessels after heart attacks.
-
healthWeight-Loss Drugs Show Promise in Heart Attack Recovery
New study reveals GLP-1 drugs may significantly improve recovery and reduce complications for heart attack patients, offering cardiovascular benefits beyond weight loss.